

# Rubra Medicaments Limited

Statement of Standalone Unaudited Financial Results for the quarter and Half year ended September 30, 2021

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		30-Sep-2021	30-Jun-2021	30-Sep-2020	30-Sep-2021	30-Sep-2020	31-Mar-2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	26.00	69.61	8.75	95.61	8.75	48.50
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
III	<b>Total Income (I + II)</b>	<b>26.00</b>	<b>69.61</b>	<b>8.75</b>	<b>95.61</b>	<b>8.75</b>	<b>48.50</b>
IV	<b>Expenses:</b>						
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	50.07	0.00	50.07	0.00	8.26
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	7.52	0.77	0.60	8.29	1.20	19.54
	Finance Costs	0.01	0.01	0.01	0.02	0.01	0.04
	Depreciation & amortisation expense	0.04	0.04	0.08	0.08	0.08	0.16
	Other Expenses	16.42	17.81	7.45	34.23	7.45	19.68
	<b>Total Expenses (IV)</b>	<b>23.99</b>	<b>68.70</b>	<b>8.14</b>	<b>92.69</b>	<b>8.74</b>	<b>47.68</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>2.01</b>	<b>0.91</b>	<b>0.61</b>	<b>2.92</b>	<b>0.01</b>	<b>0.82</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>2.01</b>	<b>0.91</b>	<b>0.61</b>	<b>2.92</b>	<b>0.01</b>	<b>0.82</b>
VIII	Tax Expense:						
	(1) Current tax	0.60	0.20	0.00	0.80	0.00	0.25
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>1.41</b>	<b>0.71</b>	<b>0.61</b>	<b>2.12</b>	<b>0.01</b>	<b>0.57</b>
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit/(loss) from Discontinuing operations (after tax )(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>1.41</b>	<b>0.71</b>	<b>0.61</b>	<b>2.12</b>	<b>0.01</b>	<b>0.57</b>
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	<b>Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>1.41</b>	<b>0.71</b>	<b>0.61</b>	<b>2.12</b>	<b>0.01</b>	<b>0.57</b>
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.03	0.01	0.01	0.04	0.00	0.01
	(2) Diluted	0.03	0.01	0.01	0.04	0.00	0.01
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.06
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.06
XVIII	Earnings per equity share (for discontinued & continuing operation):						
	(1) Basic	0.03	0.01	0.01	0.04	0.00	0.01
	(2) Diluted	0.03	0.01	0.01	0.04	0.00	0.01
1	<b>NOTES:</b>						
2.	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
	The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Rubra Medicaments Limited

Place: Mumbai  
Date: November 11, 2021

Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429

**RUBRA MEDICAMENTS LIMITED**

(Rs. in Lakhs)

**STATEMENT OF ASSETS AND LIABILITIES**

	Particulars	Figures as at the end of	
		current reporting period	
		30-Sep-21	31-Mar-21
		Unaudited	Audited
	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	1.28	1.36
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
	<b>Total non-current assets</b>	<b>1.28</b>	<b>1.36</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	48.85	22.05
	(iii) Cash and cash equivalents	1.38	0.86
	(iv) Bank balances other than (iii) above	0.01	50.77
	(v) Loans	47.12	11.50
	(vi) Others to be specified	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	4.83	3.93
	<b>Total current assets</b>	<b>102.19</b>	<b>89.11</b>
	<b>Total assets</b>	<b>103.47</b>	<b>90.47</b>
<b>1</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-482.94	-485.06
	<b>Total equity</b>	<b>63.89</b>	<b>61.77</b>
	<b>LIABILITIES</b>		
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	0.04	0.04
	(d) Other non-current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>0.04</b>	<b>0.04</b>
	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	3.54	0.12
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	36.00	-
	(b) Other current liabilities	-	-
	(c) Provisions, current	-	28.54
	(d) Current tax liabilities (Net)	-	-
	<b>Total current liabilities</b>	<b>39.54</b>	<b>28.66</b>
	<b>Total liabilities</b>	<b>39.58</b>	<b>28.70</b>
	<b>Total Equity and Liabilities</b>	<b>103.47</b>	<b>90.47</b>

For Rubra Medicaments Limited

Place: Mumbai

Date: November 11, 2021

Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429

**RUBRA MEDICAMENTS LIMITED**

**CASH FLOW STATEMENT FOR THE YEAR ENDED SEPTEMBER 30, 2021**

	Particulars	September 30, 2021	March 31, 2021
		In Lakh	In Lakh
<b>A</b>	<b><u>Cash Flow From Operating Activities</u></b>		
	Net Profit before tax and Extraordinary Items	2.92	0.81
	<b>Adjustment for :</b>		
	Depreciation	0.08	0.16
	Operating Profit before working Capital Changes	3.00	0.97
	<b>Adjustment for Capital Changes:</b>		
	Increase/Decrease in Payables & Provisions	7.46	14.48
	Increase/Decrease in Fixed Assets	0.00	0.00
	Cash Generated From Operations	<b>10.46</b>	<b>15.45</b>
	Income Tax / Deferred Tax Paid	0.80	0.25
	Extraordinary items	0.00	0.00
	<b><u>Net cash from Operating Activities</u></b>	<b>9.66</b>	<b>15.20</b>
<b>B</b>	<b><u>Net Cash From Investing Activities</u></b>	-	-
<b>C</b>	<b><u>Cash Flow From Financing Activities</u></b>		
	Increase/Decrease in Trade Payables	3.42	0.12
	Increase/Decrease in Cash Loans and advances	-36.52	29.28
	Increase/Decrease in Trade Receivables	-26.80	6.95
	<b><u>Net Cash From Financing Activities</u></b>	<b>-59.90</b>	<b>36.35</b>
	Net Increase (Decrease) in cash & cash equivalents (A+B)	<b>-50.24</b>	<b>51.55</b>
	Opening Balance of Cash & Cash Equivalents	51.63	0.08
	Closing Balance of Cash & Cash Equivalents	1.39	51.63

As per our Report of even date.

0.00

0.00

**For and on behalf of Board of Directors  
Rubra Medicaments Ltd**

Mumbai  
Date: November 11, 2021

**Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429**